D-galactonamide | 7256-14-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-galactonamide
• 英文别名: D-Galaktonsaeure-amid；D-Galaktonamid；D-galactonic acid amide；D-galacto-2,3,4,5,6-Pentahydroxy-hexansaeure-amid；D-Galactonsaeure-amid；D-Galactonamid；(2R,3S,4S,5R)-2,3,4,5,6-pentahydroxyhexanamide
• CAS: 7256-14-6
• 化学式: C₆H₁₃NO₆
• 分子量: 195.172
• InChiKey: JCZPMGDSEAFWDY-MGCNEYSASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  144
• 氢给体数：
  6
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  D-galactonamide 在 sodium hypochlorite 作用下， 生成 D-来苏糖
  参考文献：
  名称：

  Weerman, Recueil des Travaux Chimiques des Pays-Bas, 1918, vol. 37, p. 34

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 氨 作用下， 生成 D-galactonamide
  参考文献：
  名称：

  Weerman, Recueil des Travaux Chimiques des Pays-Bas, 1918, vol. 37, p. 34

  摘要：

  DOI：

文献信息

• [EN] siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS<br/>[FR] ARNSI POSSÉDANT AU MOINS DEUX LIGANDS À DEUX EXTRÉMITÉS DISTINCTES
  申请人：SILENCE THERAPEUTICS GMBH

  公开号：WO2019193189A1

  公开（公告）日：2019-10-10

  There is provided inter alia a conjugate for inhibiting expression of a target gene in a cell, said conjugate comprising a nucleic acid portion and ligand portions, said nucleic acid portion comprising at least one duplex region that comprises at least a portion of a first RNA strand and at least a portion of a second RNA strand that is at least partially complementary to the first strand, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from said target gene, said ligand portions comprising a linker moiety and a targeting ligand for in vivo targeting of cells and being conjugated exclusively to the 3' and/or 5' ends of one or both RNA strands, wherein the 5' end of the first RNA strand is not conjugated, wherein: (i) the second RNA strand is conjugated at the 5' end to the targeting ligand, and wherein (a) the second RNA strand is also conjugated at the 3' end to the targeting ligand and the 3' end of the first RNA strand is not conjugated; or (b) the first RNA strand is conjugated at the 3' end to the targeting ligand and the 3' end of the second RNA strand is not conjugated; or (c) both the second RNA strand and the first RNA strand are also conjugated at the 3' ends to the targeting ligand; or (ii) both the second RNA strand and the first RNA strand are conjugated at the 3' ends to the targeting ligand and the 5' end of the second RNA strand is not conjugated.

  提供了一种用于抑制细胞中靶基因表达的共轭物，该共轭物包括核酸部分和配体部分，所述核酸部分包括至少一个双链区域，该区域包括至少部分第一RNA链和至少部分第二RNA链，该第二RNA链至少部分与第一链互补，其中所述第一链至少部分与从所述靶基因转录的RNA的至少部分互补，所述配体部分包括连接子基团和用于体内细胞靶向的靶向配体，并且仅连接到一个或两个RNA链的3'和/或5'末端，其中第一RNA链的5'末端未连接，其中：(i) 第二RNA链在5'末端连接到靶向配体，其中(a) 第二RNA链还在3'末端连接到靶向配体，且第一RNA链的3'末端未连接；或(b) 第一RNA链在3'末端连接到靶向配体，且第二RNA链的3'末端未连接；或(c) 第二RNA链和第一RNA链的3'末端均连接到靶向配体；或(ii) 第二RNA链和第一RNA链的3'末端均连接到靶向配体，且第二RNA链的5'末端未连接。
• [EN] MONOCLONAL IGM ANTIBODIES FROM ENTIRELY CARBOHYDRATE CONSTRUCTS<br/>[FR] ANTICORPS IGM MONOCLONAUX PRODUITS À PARTIR DE CONSTRUCTIONS ENTIÈREMENT GLUCIDIQUES
  申请人：UNIV TOLEDO

  公开号：WO2018053468A1

  公开（公告）日：2018-03-22

  Entirely carbohydrate immunogens, monoclonal antibodies generated from immune responses to entirely carbohydrate immunogens, vaccine compositions, pharmaceutical compositions, and methods of making and using the same, are described.

  完全碳水化合物免疫原，由对完全碳水化合物免疫原的免疫反应产生的单克隆抗体，疫苗组合物，药用组合物以及制备和使用它们的方法被描述。
• [EN] NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL<br/>[FR] ACIDES NUCLÉIQUES POUR INHIBER L'EXPRESSION DE PROS1 DANS UNE CELLULE
  申请人：UNIV BERN

  公开号：WO2020225301A1

  公开（公告）日：2020-11-12

  The invention relates to nucleic acid products that interfere with PROS1 gene expression or inhibit its expression. The nucleic acids are particularly for use in the treatment, prevention or reduction of risk of suffering from a bleeding disorder.

  该发明涉及干扰PROS1基因表达或抑制其表达的核酸产品。这些核酸特别用于治疗、预防或减少患出血障碍的风险。
• [EN] NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL<br/>[FR] ACIDES NUCLÉIQUES POUR INHIBER L'EXPRESSION DE CNNM4 DANS UNE CELLULE
  申请人：SILENCE THERAPEUTICS GMBH

  公开号：WO2021239825A1

  公开（公告）日：2021-12-02

  The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.

  本发明涉及与干扰或抑制CNNM4（Cyclin M4）基因表达有关的核酸产品。它进一步涉及使用CNNM4抑制剂治疗疾病，例如肝病，包括非酒精性脂肪性肝病（NAFLD），非酒精性脂肪性肝炎（NASH），肝脂肪变性，肝纤维化，肝硬化，肝癌和其他与镁离子调节失调有关的疾病。
• Direct Oxidative Amidation of Aldoses by Iodine in Ammonia Water
  作者：Ming-Yi Chen、Jue-Liang Hsu、Jiun-Jie Shie、Jim-Min Fang

  DOI：10.1002/jccs.200300018

  日期：2003.2

  aldohexoses and the benzylated derivatives reacted with iodine in ammonia water at room temperature to give their corresponding saccharide amides in high yields. The reactions proceeded with oxidation of the aldose hemiacetals by iodine to generate the saccharide lactone intermediates, which underwent ammonolysis in situ to give the saccharide amides.

  戊醛糖、己醛糖和苄基化衍生物在室温下与氨水中的碘反应，以高产率得到相应的糖酰胺。反应继续进行，醛糖半缩醛被碘氧化生成糖内酯中间体，该中间体经过原位氨解得到糖酰胺。